Drs. Dingwei Ye and Yao Zhu join the show to discuss drug development in China amid the recent surge of GU clinical trials. Drs. Alicia Morgans and Chuck Ryan join the show to discuss their new podcast. Dr. Elena Castro of Virgen de la Victoria University Hospital in Malaga, Spain joins Tom and Brian to discuss PSMAFore data. Dr. Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer. Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer. Brian and Tom discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings. Dr. John Heymach discusses a novel PD1/VEGF bispecific agent in lung cancer and its potential applications in GU oncology. Dr. Chuck Ryan of Memorial Sloan Kettering Cancer Center joins us to discuss Dr. Felix Feng's keynote address. Silke Gillessen joins the podcast to discuss the top areas of consensus and controversy from APCCC 2025. Dr. Tyler Seibert provides updates from the 2025 APCC Diagnostics conference. Dr. Silke Gillessen joins the show to discuss some of the top highlights from this year's ASCO GU conference. Returning guest Dr. Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor. Dr. Vincent Xu of Dana-Farber Cancer Institute discusses this emerging RCC biomarker and data from the Checkmate 214 trial. Returning guest Dr. Laurence Albiges discusses novel combos in refractory RCC and gives an update on COSMIC-313. Dr. Gopa Iyer of Memorial Sloan Kettering Cancer Center joins the show to discuss his initial results. Dr. Matt Galsky joins the show to discuss pathological complete response rates from the NIAGARA trial. Dr. Xinan Sheng joins the podcast to discuss the update of this trial and impressive pCR rates. Dr. Tanya Dorff discussed results of the STOPCAP trial from ASCO GU 2025, along with new data from TALAPRO-2. Dr. Neeraj Agarwal joins Tom and Brian for an in-depth look at important data from TALAPRO-2. Silke Gillessen joins Brian and Tom to discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.